



Uploaded to the VFC Website

▶▶▶ 2016 ◀◀◀

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

If Veterans don't help Veterans, who will?

Note:

VFC is not liable for source information in this document, it is merely provided as a courtesy to our members & subscribers.



Troponin T test provides possible one hour diagnosis of heart attack

Published on January 15, 2016 at 9:24 AM

Results from the TRAPID-AMI clinical study have been published online by the Annals of Emergency Medicine, confirming a novel approach for a more rapid diagnosis of heart attack in patients with acute chest pain.

The strategy is based on the cardiac troponin T high-sensitivity test from Roche and reduces the observation time needed to rule-in or rule-out a heart attack from 3-6 hours to just 1 hour.

It is well established that a fast and reliable diagnosis of heart attack is critical because every hour of delay from the onset of symptoms to treatment increases the mortality risk.

Thanks to this new approach, we can now shorten the time to heart attack diagnosis for millions of patients presenting in emergency rooms with acute chest pain all over the world,"

"Patients no longer have to wait for three or more hours in the emergency department, not knowing whether they have an acute, life-threatening disease or if their chest pain is caused by other reasons."

Christian Mueller, professor of cardiology at the University of Basel, Switzerland, one of the study's principal investigators.

Every minute counts

A heart attack, or acute myocardial infarction (AMI), is a common cardiac event in which the blood supply to an area of the heart muscle is interrupted, causing the muscle cells to die.

Prompt treatment is essential as every 30 minutes of delay increases the relative risk of mortality by 7.5 % in patients with AMI. Patients with chest pain and other symptoms suggestive of AMI account for approximately 10-20% of all emergency room consultations and every 43 seconds, someone in the United States will have a heart attack.

Troponin is a heart muscle protein that is released into the blood stream during a heart attack. A limitation of the earlier generations of blood tests was the time required to detect the troponin release, sometimes requiring up to six hours with less sensitive troponin tests.

The mortality rate of heart attacks is highest within hours of onset, so an early diagnosis and initiation of treatment greatly impacts outcome and potentially saves lives.

The European Society of Cardiology adopted this accelerated diagnostic concept at their annual meeting held in London (UK) in August 2015. Their new clinical practice guidelines (2015 ESC NSTEMI) now support the 1-hour diagnostic algorithm with high-sensitive troponin testing validated in the TRAPID-AMI study.

Results of the TRAPID-AMI study once again demonstrate how diagnostics can influence clinical practice to contribute to better patient outcomes,"

"At Roche, we continuously invest in clinical studies to foster innovation and to advance healthcare. We provide physicians and patients around the world with diagnostic tests and solutions that improve health and save lives."

Roland Diggelmann, Chief Operating Officer of Roche Diagnostics.

Source:

[Roche](http://www.roche.com)

Roche Diagnostics Limited



Industriestrasse 7

Forrenstrasse

Rotkreuz 6343

Switzerland

PH: 41 (41) 799 22 44

Email: info@roche-diagnostics.ch

Visit [Roche Diagnostics Limited](#) Website

Company Background

Along with Roche Pharmaceuticals, Roche Diagnostics is an important part of the foundation that modern healthcare builds upon. Our broad range of innovative diagnostic tests and systems play a pivotal role in the groundbreaking area of integrated healthcare solutions and cover the early detection, targeted screening, evaluation and monitoring of disease. Roche Diagnostics is active in all market segments, from scientific research and clinical laboratory systems to patient self-monitoring.